# EDGAR Filing Document

**Accession Number:** 0001402328
**File Stem:** 0001683168-26-002781
**Filing Date:** 2026-4
**Character Count:** 9536
**Document Hash:** c01bf716060593579f6c8f759388fd5a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-002781.hdr.sgml**: 20260409

**ACCESSION NUMBER**: 0001683168-26-002781

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260406

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260409

**DATE AS OF CHANGE**: 20260409

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sunshine Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001402328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 205566275
- **STATE OF INCORPORATION:** CO
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41282
- **FILM NUMBER:** 26851587

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAS OLAS WAY
- **STREET 2:** CU4 SUITE 433
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** 954-330-0684

**MAIL ADDRESS:**
- **STREET 1:** 333 LAS OLAS WAY
- **STREET 2:** CU4 SUITE 433
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sunshine Biopharma, Inc
- **DATE OF NAME CHANGE:** 20091102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mountain West Business Solutions, Inc
- **DATE OF NAME CHANGE:** 20071030

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** mountain west business solutions,inc
- **DATE OF NAME CHANGE:** 20070607

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **<u>April 6, 2026</u>**

**<u>SUNSHINE BIOPHARMA INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **<u>Colorado</u>** | **<u>001-41282</u>** | **<u>20-5566275</u>** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer ID No.) |

---

**333 Las Olas Way**

**CU4 Suite 433**

**<u>Fort Lauderdale</u>** **<u>, FL</u> <u>33301</u>**

(Address of principal executive offices) (zip code)

**<u>(954) 330-0684</u>**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
| Common Stock, par value $0.001 | SBFM | The Nasdaq Stock Market LLC |
| Common Stock Purchase Warrants | SBFMW | The Nasdaq Stock Market LLC |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02 Results of Operations and Financial Condition.**

On April 6, 2026, Sunshine Biopharma Inc. (the "Company") issued a press release announcing the Company's financial results for the year ended December 31, 2025. The press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No**. | **Description** |
| 99.1 | [Press Release](sunshine_ex9901.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Dated: April 9, 2026 | **SUNSHINE BIOPHARMA INC.** |
|  | By: <u>/s/ Dr. Steve N. Slilaty&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Dr. Steve N. Slilaty, Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](image_001.jpg)

**Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year**

FORT LAUDERDALE, FL / ACCESSWIRE / April 6, 2026 — Sunshine Biopharma Inc. (NASDAQ: SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life-saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

**2025 Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Revenue of $36.3 million, representing a 4.1% increase compared to 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· $2.46 million in gross proceeds raised through a registered direct offering to
support expansion of sales operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Nine new generic prescription drugs launched, expanding the Company's portfolio
in oncology, cardiovascular health, central nervous system disorders, and antimicrobials.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Advancement of proprietary antiviral research, including a new series of orally
active, non-covalent PLpro protease inhibitors that demonstrated dose-dependent antiviral activity in SARS-CoV-2-infected mice, strong
potency in cellular models, and favorable pharmacokinetics.

**Management Commentary**

"We are pleased with our accomplishments in 2025, as we remain committed to reaching profitability in the near future," said Dr. Steve Slilaty, CEO. "Looking ahead, we are excited about the opportunities for growth in 2026 and beyond as we continue expanding our generic drug portfolio and advancing our proprietary drug development programs to deliver more life-saving medicines to the market."

**Financial Summary (in millions)**

---

| | | |
|:---|:---|:---|
|  | **2025** | **2024** |
| Revenue | $36.31 | $34.87 |
| Gross Profit | $12.26 | $10.67 |
| General & Administrative Expenses | $18.48 | $16.48 |
| Net Loss | $5.98 | $5.13 |

---

The increase in General & Administrative Expenses in 2025 was primarily driven by a non-cash, non-recurring impairment charge of $1.75 million related to intangible assets. Excluding this charge, the Company's operating performance reflects a meaningful improvement over 2024.

In January 2026, Sunshine Biopharma implemented cost-reduction initiatives aimed at lowering general and administrative expenses and sharpening the Company's focus on achieving near-term profitability. Based on current plans, these initiatives are expected to reduce expenses by approximately $2 million to $3 million in 2026, although there can be no assurance that these reductions will be fully realized.

**About Sunshine Biopharma**

Sunshine Biopharma currently markets 71 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:

· K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer.

· PLpro protease inhibitor, a small-molecule antiviral candidate for SARS-related
coronavirus infections.

Additional information is available at www.sunshinebiopharma.com.

**Forward-Looking Statements**

This press release contains forward-looking statements based on current expectations, forecasts, and assumptions that involve risks and uncertainties. These statements include, but are not limited to, those regarding the Company's financial performance, drug development activities, and future growth opportunities. Actual results may differ materially due to various risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission. Readers are encouraged to review the Company's most recent SEC filings for additional information.

**Contact:**

Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com